Loading clinical trials...
Loading clinical trials...
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT06289491 · Glaucoma, Glaucoma, Open-Angle
NCT07217678 · Glaucoma, Open-Angle Glaucoma, and more
NCT07390890 · Primary Open Angle Glaucoma, Ocular Hypertension
NCT05902871 · Primary Open Angle Glaucoma, Ocular Hypertension, and more
NCT05885022 · Glaucoma, Open-Angle
Pfizer Investigational Site
Ekenäs
Pfizer Investigational Site
Helsinki
Pfizer Investigational Site
Helsinki
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions